, but n the
Section 1: Multiple Choice - Question 4
What is the most likely difference between the signaling pathways of a patient that has cancer but
has not been provided cyclopamine and one that has cancer and has been provided with
cyclopamine?
hibits
of
A
In the patient who has been provided cyclopamine, patched (Ptc) will be unable
to bind to Smo, and thus the HSC complex would be activated.
result
AS
cion of
and
B
In the patient who has been provided cyclopamine, the Ci transcription factor
will be able to activate certain genes within the cell nucleus.
dgehog
t
In the patient who has not been provided with cyclopamine, the HSC complex
will be active, therefore allowing Ci to initiate transcription of relevant genes.
roteins
D
In the patient who has not been provided with cyclopamine, the HSC complex
will be inactivated due to Smo being inhibited by Patched (Ptc),